IPO registrations (S-1, F-1) · Registrants
BIOCANCELL THERAPEUTICS INC.
- SEC CIK
- 1451980 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2008-12-17, last 2011-03-31; 3 initial registrations, 17 amendments
- Outcome
- Final prospectus filed 2010-11-22; declared effective 2009-06-22
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Business address
- BECK SCIENCE CENTER, 8 HARTOM STREET, HAR HOTZVIM, Jerusalem, L3 97775
- EIN
- 20-4630076
- EDGAR entity type
- operating
- Insiders and CEO pay
- BIOCANCELL THERAPEUTICS INC. on the corporate pages
Offering terms
- Shares offered
- 563,497
- Listing
- under the symbol BICL
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: BIOCANCELL THERAPEUTICS INC. EXACT (CIK (EXACT))
Filings 31
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2008-12-17 | S-1 | S-1 (registration) | BIOCANCELL THERAPEUTICS INC. | 0001144204-08-069912 ↗ |
| 2009-02-02 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001144204-09-004512 ↗ |
| 2009-04-07 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001144204-09-019319 ↗ |
| 2009-04-21 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001144204-09-021706 ↗ |
| 2009-05-05 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001144204-09-024203 ↗ |
| 2009-06-09 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001144204-09-031696 ↗ |
| 2009-06-22 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-09-001720 ↗ |
| 2009-09-24 | S-1 | S-1 (registration) | BIOCANCELL THERAPEUTICS INC. | 0001451980-09-000012 ↗ |
| 2009-10-21 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-09-000018 ↗ |
| 2009-12-04 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-09-000052 ↗ |
| 2010-03-25 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000010 ↗ |
| 2010-05-07 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-10-001421 ↗ |
| 2010-06-11 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000028 ↗ |
| 2010-07-22 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000032 ↗ |
| 2010-07-29 | S-1 | S-1 (registration) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000036 ↗ |
| 2010-08-24 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000050 ↗ |
| 2010-10-07 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000057 ↗ |
| 2010-10-29 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000067 ↗ |
| 2010-11-05 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000074 ↗ |
| 2010-11-09 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000076 ↗ |
| 2010-11-12 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001178913-10-003004 ↗ |
| 2010-11-12 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-10-003213 ↗ |
| 2010-11-17 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-10-003280 ↗ |
| 2010-11-22 | 424B4 | 424B4 (final prospectus) | BIOCANCELL THERAPEUTICS INC. | 0001451980-10-000090 ↗ |
| 2011-03-31 | S-1/A | S-1/A (amendment) | BIOCANCELL THERAPEUTICS INC. | 0001451980-11-000017 ↗ |
| 2011-04-13 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-11-000996 ↗ |
| 2011-04-13 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-11-000998 ↗ |
| 2011-06-20 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-11-001892 ↗ |
| 2012-08-10 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-12-002444 ↗ |
| 2012-08-10 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-12-002445 ↗ |
| 2012-08-10 | EFFECT | EFFECT (declared effective) | BIOCANCELL THERAPEUTICS INC. | 9999999995-12-002448 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2010-11-12 | S-1/A | registration statement | 560,000 | - | BICL | 0 | primary document; shares headline | document ↗ | ||
| 2010-11-22 | 424B4 | final prospectus | 563,497 | - | BICL | 0 | primary document; shares headline | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Barak Avi | Director,Officer | Chief Executive Officer | 2 | 2009 | |
| Boim Aviv | Director; Director,TenPercentOwner | 2 | 2009–2010 | ||
| Epstein Nava | Director | 1 | 2009 | ||
| Goldberg Ofer | Director | 2 | 2009–2011 | ||
| Hochberg Abraham | Director,Officer; Director,Officer,TenPercentOwner | Chief Scientist | 3 | 2009–2012 | |
| Landsberg Moshe | Officer | Vice President of Technology | 2 | 2009 | |
| Levitzki Alexander | Director | 2 | 2009 | ||
| NEVO DORON | Director | 5 | 2009–2011 | ||
| Ohana Patricia | Officer | VP Clinical Development; VP, Clinical Development; VP of Clinical Development | 3 | 2009–2011 | |
| Rappaport Hanoch | Director | 3 | 2009–2011 | ||
| TIKCRO TECHNOLOGIES LTD | TenPercentOwner | 1 | 2009 | ||
| Weinstein Ira | Officer | CFO and COO; CFO & COO | 3 | 2009–2011 | |
| Ben Gur Jacob | Director | 1 | 2009 | ||
| Bergman Shelly | TenPercentOwner | 3 | 2009–2012 | ||
| Clal Biotechnology Industries Ltd. | TenPercentOwner | 4 | 2009–2012 | ||
| CLAL INDUSTRIES & INVESTMENTS LTD | TenPercentOwner | 3 | 2009–2012 | ||
| Dankner Nochi | TenPercentOwner | 3 | 2009–2012 | ||
| IDB DEVELOPMENT CORP LTD | TenPercentOwner | 3 | 2009–2012 | ||
| IDB HOLDING CORP LTD | TenPercentOwner | 3 | 2009–2012 | ||
| Livnat Avraham | TenPercentOwner | 3 | 2009–2012 | ||
| Manor Ruth | TenPercentOwner | 3 | 2009–2012 | ||
| DANON URI | Officer | Chief Executive Officer | 2 | 2009–2010 | |
| SCHLACHET DAVID | Director | 1 | 2010 | ||
| YARKONI ORLY | Director | 1 | 2010 | ||
| Krupik Ruben | Director | 1 | 2011 | ||
| Burgin Jonathan | Officer | Chief Financial Officer | 2 | 2011–2012 | |
| Ben-Am Monique | Officer | VP Clinical Development; VP Clinical Trials | 2 | 2011–2012 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | BIOCANCELL THERAPEUTICS INC. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, L3 first:
- CANNAPOWDER, INC. L3
- Rosetta Genomics Ltd. L3
- Can-Fite BioPharma Ltd. L3
- RedHill Biopharma Ltd. L3
- KAMADA LTD L3
- MAPI - PHARMA LTD L3
- NeuroDerm Ltd. L3
- Advanced Inhalation Therapies (AIT) Ltd. L3
- Silenseed Ltd. L3
- SciSparc Ltd. L3
In other datasets, the same topic (Health) in L3:
- Form D issuer: Agada Medical Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health